key: cord-0917435-si9jqsi2
authors: Hsu, Tina; Sink, Jacquelyn R.; Alaniz, Veronica I.; Zheng, Lida; Mancini, Anthony J.
title: Acute genital ulceration after SARS-CoV-2 vaccination and infection
date: 2022-04-09
journal: J Pediatr
DOI: 10.1016/j.jpeds.2022.04.005
sha: 1883ff35a5226c656d5c1cb8359a3bc9aecf1f07
doc_id: 917435
cord_uid: si9jqsi2

Reactive, non-sexually related acute genital ulceration (AGU), also known as Lipschütz ulcer, is a non-sexually related ulceration involving the vulva, most commonly affecting girls and adolescent women in response to infection. Herein, we describe three female patients with AGU occurring after SARS-CoV-2 vaccination or natural infection.

Reactive, non-sexually related acute genital ulceration , also known as Lipschütz ulcer, is a non-sexually related ulceration involving the vulva, most commonly affecting girls and adolescent women. Although generally a diagnosis of exclusion, AGU has been reported following infections, including Epstein-Barr virus (EBV), cytomegalovirus (CMV), influenza A and B, adenovirus, and Mycoplasma pneumoniae. reactive AGU has been now reported in the setting of SARS-CoV-2 infection. Herein, we report three patients with AGU presumably triggered by SARS-CoV-2 vaccination or infection.

A 12-year-old otherwise healthy female presented with painful vulvar ulcerations that had been present for approximately five days. Review of systems was positive for dysuria and hematuria. She was initially evaluated by her pediatrician and empirically treated with oral nitrofurantoin, fluconazole, and phenazopyridine for suspected urinary tract infection. She was then referred to pediatric dermatology for further evaluation and treatment due to lack of improvement. She was otherwise healthy and was not taking any other medications, denied any history of sexual activity, and had no prior history of oral ulcers, inflammatory bowel disease, or autoimmune disease. the family reported that the patient had received her second dose of the Pfizer-BioNTech SARS-CoV-2 vaccine approximately 48 hours prior to symptom onset. The day following vaccination, she also developed subjective fevers, fatigue, and malaise lasting 24 hours. The patient was given topical clobetasol 0.05% ointment twice daily, lidocaine 2% jelly every 4-6 hours as needed, oral acetaminophen and ibuprofen as needed, and sitz baths with improvement of her symptoms. Ulcers healed over the course of two weeks.

A 14-year-old female presented to the emergency department with two days of severe vulvar pain and ulceration. Onset of symptoms occurred three days after the patient received her second dose of the Pfizer-BioNTech SARS-CoV-2 vaccine and was associated with low grade fevers. This presentation was her second episode of genital ulceration, the first having occurred several months prior following fever, headaches, and body aches. SARS-CoV-2 PCR, EBV serologies, and HSV PCR performed at the time of her first episode were all negative. We report three patients with AGU presumably triggered by SARS-CoV-2 infection or mRNA vaccination against SARS-CoV-2 . Given the current environment of misinformation and distrust surrounding vaccines, it is important to accurately report adverse side effects related to the SARS-CoV-2 vaccine. Adding more information to the medical literature regarding potential side effects of SARS-CoV-2 vaccines will allow providers to be better equipped to counsel patients should symptoms occur, including the self-limited nature of AGU, as well as to avoid potentially unnecessary diagnostic evaluations. Moreover, given the possible repercussions of misdiagnosing this condition, healthcare providers should be aware of AGU and its possible rising incidence given the prevalence of both natural SARS-CoV-2 infection and vaccination.

Reactive non-sexually related acute genital ulcers associated with COVID-19

COVID-19-related acute genital ulcers

Vulvar Aphthous Ulcer in an Adolescent with COVID-19

Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study

Vulvar Aphthous Ulcer Following Pfizer-BioNTech COVID-19 Vaccine -A Case Report

Vulvar Aphthous Ulcer in an Adolescent After Pfizer-BioNTech (BNT162b2) COVID-19 Vaccination

Oct 25;S1083-3188(21)00304-1. Online ahead of print

Vulvar aphthous ulcer after COVID-19 vaccination